NeoGenomics Financial Statements From 2010 to 2026

NEO Stock

USD 12.06 0.34 2.74%

NeoGenomics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing NeoGenomics' valuation are provided below:

Gross Profit

307.8 M

Profit Margin

(0.16)

Market Capitalization

1.6 B

Enterprise Value Revenue

2.6096

Revenue

709.2 M

We have found one hundred twenty available fundamental ratios for NeoGenomics, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check NeoGenomics' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.

NeoGenomics Total Revenue

797.63 Million

Check NeoGenomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeoGenomics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 87.6 M, Interest Expense of 8 M or Selling General Administrative of 272.7 M, as well as many indicators such as Price To Sales Ratio of 0.69, Dividend Yield of 0.0059 or PTB Ratio of 0.51. NeoGenomics financial statements analysis is a perfect complement when working with NeoGenomics Valuation or Volatility modules.

Build AI portfolio with NeoGenomics Stock

Check out the analysis of NeoGenomics Correlation against competitors.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

NeoGenomics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

2 B

1.9 B

836.1 M

Slightly volatile

Other Current Liabilities

90.6 M

86.3 M

33.8 M

Slightly volatile

Total Current Liabilities

363.7 M

346.4 M

98.6 M

Slightly volatile

Accounts Payable

26.1 M

24.8 M

15.4 M

Slightly volatile

Cash

443.2 M

422.1 M

156.4 M

Slightly volatile

Cash And Short Term Investments

467.1 M

444.9 M

190.5 M

Slightly volatile

Common Stock Total Equity

102.7 K

114.3 K

163.9 K

Slightly volatile

Common Stock Shares Outstanding

15.5 M

29.1 M

20.6 M

Slightly volatile

Liabilities And Stockholders Equity

2 B

1.9 B

836.1 M

Slightly volatile

Non Current Liabilities Total

524.6 M

499.6 M

247.6 M

Slightly volatile

Total Liabilities

888.4 M

846.1 M

346.2 M

Slightly volatile

Total Current Assets

719.7 M

685.4 M

300.5 M

Slightly volatile

Common Stock

102.7 K

115.2 K

164 K

Slightly volatile

Property Plant And Equipment Net

209.7 M

199.7 M

95.6 M

Slightly volatile

Non Current Assets Total

1.3 B

1.2 B

535.6 M

Slightly volatile

Other Current Assets

38.5 M

36.7 M

14.3 M

Slightly volatile

Other Stockholder Equity

1.5 B

1.4 B

593.6 M

Slightly volatile

Property Plant And Equipment Gross

439.1 M

418.2 M

155.5 M

Slightly volatile

Property Plant Equipment

123.8 M

117.9 M

65.7 M

Slightly volatile

Short and Long Term Debt Total

730.9 M

696.1 M

275.1 M

Slightly volatile

Other Assets

3.8 M

5.9 M

5.5 M

Slightly volatile

Net Receivables

181.8 M

173.1 M

80.8 M

Slightly volatile

Inventory

32.3 M

30.8 M

14.2 M

Slightly volatile

Short Term Debt

246.5 M

234.8 M

48.8 M

Slightly volatile

Long Term Debt

411 M

391.4 M

197.2 M

Slightly volatile

Other Liabilities

57.7 M

55 M

24.7 M

Slightly volatile

Long Term Debt Total

646.4 M

615.6 M

235.2 M

Slightly volatile

Capital Surpluse

1.4 B

1.3 B

577.9 M

Slightly volatile

Capital Lease Obligations

77.5 M

73.9 M

32.8 M

Slightly volatile

Short and Long Term Debt

242.4 M

230.9 M

88.2 M

Slightly volatile

Warrants

30.8 M

37.5 M

30.8 M

Slightly volatile

Non Current Liabilities Other

12.9 M

10.6 M

26.3 M

Slightly volatile

Net Invested Capital

845.2 M

1.7 B

619.2 M

Slightly volatile

Net Working Capital

357.5 M

339 M

214.5 M

Slightly volatile

Capital Stock

128.4 K

147.2 K

108.5 K

Slightly volatile

NeoGenomics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

87.6 M

83.4 M

35.4 M

Slightly volatile

Interest Expense

8 M

7.6 M

4.8 M

Slightly volatile

Selling General Administrative

272.7 M

259.7 M

118.4 M

Slightly volatile

Total Revenue

797.6 M

759.7 M

339.7 M

Slightly volatile

Gross Profit

350.3 M

333.6 M

145.8 M

Slightly volatile

Other Operating Expenses

908.9 M

865.6 M

379.7 M

Slightly volatile

Cost Of Revenue

447.3 M

426 M

193.9 M

Slightly volatile

Total Operating Expenses

461.5 M

439.5 M

185.1 M

Slightly volatile

Research Development

37.6 M

35.8 M

13.2 M

Slightly volatile

Selling And Marketing Expenses

102.2 M

97.3 M

41.4 M

Slightly volatile

Non Recurring

2.4 M

4.1 M

3.7 M

Pretty Stable

Interest Income

22.3 M

21.2 M

7.2 M

Slightly volatile

Preferred Stock And Other Adjustments

8.8 M

11.7 M

6.7 M

Slightly volatile

Reconciled Depreciation

52 M

83.4 M

39.5 M

Slightly volatile

Extraordinary Items

2.4 M

2.7 M

2.9 M

Slightly volatile

NeoGenomics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Begin Period Cash Flow

413.6 M

393.9 M

132.7 M

Slightly volatile

Depreciation

87.6 M

83.4 M

35 M

Slightly volatile

End Period Cash Flow

443.2 M

422.1 M

157.6 M

Slightly volatile

Stock Based Compensation

40.3 M

38.4 M

13.5 M

Slightly volatile

Issuance Of Capital Stock

4 M

4.2 M

121.7 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

0.69

0.73

0.8812

Pretty Stable

Dividend Yield

0.0059

0.0067

0.0073

Slightly volatile

Days Sales Outstanding

70.32

74.86

94.3634

Slightly volatile

Average Payables

1.6 M

Slightly volatile

Stock Based Compensation To Revenue

0.0478

0.0455

0.0291

Slightly volatile

Capex To Depreciation

0.46

0.51

0.5575

Pretty Stable

EV To Sales

1.08

1.14

1.1481

Slightly volatile

Inventory Turnover

20.8

15.93

15.468

Very volatile

Days Of Inventory On Hand

17.74

23.72

25.1649

Very volatile

Payables Turnover

16.2

15.43

11.4623

Slightly volatile

Sales General And Administrative To Revenue

0.72

0.39

0.6116

Slightly volatile

Average Inventory

516.6 K

492 K

510.4 K

Slightly volatile

Research And Ddevelopement To Revenue

0.0689

0.0542

0.0625

Slightly volatile

Capex To Revenue

0.0679

0.0715

0.222

Slightly volatile

Cash Per Share

14.43

13.74

7.6102

Slightly volatile

Payout Ratio

1.66

1.87

2.0448

Slightly volatile

Days Payables Outstanding

23.26

24.48

36.8069

Slightly volatile

Intangibles To Total Assets

0.35

0.47

0.3984

Slightly volatile

Current Ratio

1.82

1.78

3.1205

Slightly volatile

Receivables Turnover

5.09

5.05

4.1175

Slightly volatile

Debt To Equity

1.19

0.77

0.6415

Very volatile

Capex Per Share

1.53

1.46

0.9016

Slightly volatile

Average Receivables

4.7 M

4.4 M

4.6 M

Slightly volatile

Revenue Per Share

24.64

23.47

15.2393

Slightly volatile

Interest Debt Per Share

22.83

21.74

11.3516

Slightly volatile

Debt To Assets

0.36

0.42

0.2896

Slightly volatile

Graham Number

1.1

2.12

1.503

Slightly volatile

Operating Cycle

88.06

98.58

120

Slightly volatile

Days Of Payables Outstanding

23.26

24.48

36.8069

Slightly volatile

Dividend Payout Ratio

1.66

1.87

2.0448

Slightly volatile

Long Term Debt To Capitalization

0.5

0.31

0.3636

Pretty Stable

Total Debt To Capitalization

0.56

0.46

0.3644

Very volatile

Debt Equity Ratio

1.19

0.77

0.6415

Very volatile

Quick Ratio

1.72

1.7

2.9544

Slightly volatile

Cash Ratio

0.76

1.1

1.372

Slightly volatile

Days Of Inventory Outstanding

17.74

23.72

25.1649

Very volatile

Days Of Sales Outstanding

70.32

74.86

94.3634

Slightly volatile

Fixed Asset Turnover

3.54

3.42

4.3495

Slightly volatile

Debt Ratio

0.36

0.42

0.2896

Slightly volatile

Price Sales Ratio

0.69

0.73

0.8812

Pretty Stable

Asset Turnover

0.44

0.46

80.5524

Slightly volatile

Gross Profit Margin

0.26

0.4

0.4124

Pretty Stable

NeoGenomics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

654.9 M

736.8 M

804.2 M

Slightly volatile

NeoGenomics Fundamental Market Drivers

	Forward Price Earnings	222.2222
	Cash And Short Term Investments	386.8 M

NeoGenomics Upcoming Events

	22nd of February 2024 Upcoming Quarterly Report	View
	13th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	22nd of February 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About NeoGenomics Financial Statements

NeoGenomics investors utilize fundamental indicators, such as revenue or net income, to predict how NeoGenomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	470.4 K	493.9 K
Total Revenue	759.7 M	797.6 M
Cost Of Revenue	426 M	447.3 M
Stock Based Compensation To Revenue	0.05	0.05
Sales General And Administrative To Revenue	0.39	0.72
Research And Ddevelopement To Revenue	0.05	0.07
Capex To Revenue	0.07	0.07
Revenue Per Share	23.47	24.64
Ebit Per Revenue	(0.14)	(0.13)

Pair Trading with NeoGenomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.

Moving against NeoGenomics Stock

0.73	DVA	DaVita HealthCare	Pair Corr
0.69	BZ7A	Bumrungrad Hospital	Pair Corr
0.67	210518DE3	US210518DE35	Pair Corr
0.59	SIG	Sigma Healthcare	Pair Corr
0.58	7QD	CLOVER HEALTH INV	Pair Corr

The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.

The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:

How To Invest In NeoGenomics

Details

Is NeoGenomics Stock a good investment?

Details

What is NeoGenomics' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of NeoGenomics Correlation against competitors.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Quarterly Earnings Growth

1.306

Earnings Share

(0.87)

Revenue Per Share

5.552

Quarterly Revenue Growth

0.119

Return On Assets

(0.03)

Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.

It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

NeoGenomics Financial Statements From 2010 to 2026

NeoGenomics Total Revenue

797.63 Million

NeoGenomics Balance Sheet

NeoGenomics Income Statement

NeoGenomics Cash Flow Statement

Financial Ratios

NeoGenomics Valuation Data

NeoGenomics Fundamental Market Drivers

NeoGenomics Upcoming Events

About NeoGenomics Financial Statements

Pair Trading with NeoGenomics

Moving against NeoGenomics Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY